3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
3
sargramostim
2
pembrolizumab
2
atezolizumab
2
Platinum
2
Cyclophosphamide
2
tazemetostat
1
regorafenib
1
enzalutamide
1
entinostat
1
durvalumab
1
cemiplimab
1
cabozantinib
1
avelumab
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Pemetrexed
1
Paclitaxel
1
Microarray Analysis
1
Levoleucovorin
1
Leucovorin
1
Ipilimumab
1
Interleukin-2
1
Interferon-gamma
1
Interferon-alpha
1
In Situ Hybridization, Fluorescence
1
Immunoenzyme Techniques
1
Immune Checkpoint Inhibitors
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Gene Expression Profiling
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma, Malignant
×
Blood Component Removal
×
Genitourinary
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled